Maryam Lustberg, MD, MPH

home / authors / maryam-lustberg-md-mph

Articles

Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg

Caroline Seymour;Brian Rini, MD;Jonathan C. Trent, MD, PhD;Maryam Lustberg, MD, MPH;Pamela L. Kunz, MD;Jason Luke, MD;Mark A. Lewis, MD

June 6th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Unmet Needs and the Future of HER2+ Breast Cancer Treatment

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

March 6th 2023

The panel closes their discussion by summarizing the most exciting recent advances in HER2+ breast cancer, the future of treatment, and unmet needs that must be addressed.

Emerging Data and Investigational Agents in HER2+ mBC

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

March 6th 2023

The panel highlights emerging data from SABCS 2022 on investigational agents being explored for HER2+ mBC treatment.

Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

March 6th 2023

The panel discusses the management of patients with HER2+ mBC with asymptomatic brain mets and shares their thoughts on the use of surveillance brain MRI in this setting.

Second-Line Treatment of HER2+ mBC and Recent Data Updates

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

February 27th 2023

Maryam Lustberg, MD, MPH introduces the standard of care regimens for the second-line treatment of HER2+ metastatic breast cancer, followed by a discussion of recent data on the ADC trastuzumab deruxtecan (T-DXd).

Options for Third- and Further-Line Treatment of HER2+ mBC

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

February 27th 2023

Dr Debu Tripathy explains the treatment options for patients with HER2+ metastatic breast cancer in the third-line and later-line settings, including combination tucatinib/trastuzumab/capecitabine.

Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

February 21st 2023

The panel highlights recent data updates in adjuvant treatment of HER2+ early breast cancer, including longer-term follow-up data from the APT and ATEMPT trials.

HER2+ mBC: First-Line Treatment Regimens

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

February 21st 2023

A focused discussion on available options for the first-line treatment of HER2+ metastatic breast cancer (mBC), with reference to data from the CLEOPATRA trial.

Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

February 13th 2023

Joyce O’Shaughnessy, MD, starts a conversation on which patients with HER2+ early breast cancer are the best candidates for extended adjuvant neratinib therapy.

Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

February 13th 2023

A review of recently reported data on the use of adjuvant pertuzumab/trastuzumab for the treatment of HER2+ early breast cancer, including data from the APHINITY and PHranceSCa trials.

Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

February 7th 2023

The panel explains their clinical experiences with using the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) to treat HER2+ early breast cancer.

Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

February 7th 2023

A look at how patient response to neoadjuvant treatment for HER2+ early breast cancer informs adjuvant treatment selection.

Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

January 30th 2023

The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.

De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

January 30th 2023

Debu Tripathy, MD, details when he utilizes a treatment de-escalation approach in his patients with HER2+ early breast cancer.

Neoadjuvant Treatment of HER2+ Early Breast Cancer

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

January 20th 2023

A review of the standard of care regimens for the preoperative or neoadjuvant treatment of HER2+ early breast cancer.

Incidence and Typical Prognosis of HER2+ Early Breast Cancer

Joyce O’Shaughnessy, MD;Virginia Borges, MD;Maryam Lustberg, MD, MPH;Debu Tripathy, MD

January 20th 2023

Virginia Borges, MD, explains how common HER2+ early breast cancer is and the goals of treatment for patients.

Dr. Lustberg on the Real-World Use of Ovarian Suppression in HR+/HER2+ Breast Cancer

Maryam Lustberg, MD, MPH

January 5th 2023

Maryam Lustberg, MD, MPH, discusses the real-world use of ovarian suppression therapy in clinical practice for premenopausal patients with hormone receptor-positive, HER2-positive breast cancer.